SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world

Eur Heart J. 2023 Jun 25;44(24):2231-2233. doi: 10.1093/eurheartj/ehad282.

Authors

Nikolaus Marx¹, Dirk Müller-Wieland¹

Affiliation

¹ Department of Internal Medicine I, RWTH Aachen University Hospital, Pauwelsstraße 30, D-52074 Aachen, Germany.

Abstract

Graphical Abstract

Effect of SGLT2 inhibitors in patients with heart failure and type 2 diabetes. CV, cardiovascular; HF, heart failure.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cohort Studies
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucose
Heart Failure* / drug therapy
Humans
Sitagliptin Phosphate
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Sitagliptin Phosphate
Glucose
Sodium